# Patient-Trial Match Report

*Generated: 2026-01-05 06:57:39*

## Patient Profile

- **Age**: 48
- **Sex**: Female
- **Cancer Type**: breast cancer
- **Biomarkers**: HER2 positive, ER positive, PR negative

**Clinical Description**:
> 48-year-old premenopausal female with HER2-positive (IHC 3+, FISH amplified), ER+/PR- metastatic breast cancer. Originally diagnosed as Stage IIA in 2021, received neoadjuvant TCHP with pCR. Developed bone-only metastatic recurrence 2 years later. First-line trastuzumab/pertuzumab + docetaxel achieved PR, then progression at 10 months. Second-line T-DM1 ongoing x6 cycles with mixed response - new liver lesions noted. Interested in ADC combinations or novel HER2 agents. Baseline cardiac function LVEF 58%. No CNS disease. Mild neuropathy from prior taxanes.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 15
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 46
- **LLM scored**: 54

## ðŸŸ¢ HIGH Likelihood (4 trials)

### [NCT03740256](https://clinicaltrials.gov/study/NCT03740256)

**A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors**

- **Sponsor**: Baylor College of Medicine
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has HER2 positive breast cancer which matches the trial's indication for HER2 positive solid tumors.
- Patient has progressed after standard first line therapy.
- Patient is 48 years old, which meets the age requirement as patient must be â‰¥ 18 years.
- ECOG status is 1, which is acceptable for the trial.

**? Uncertainties:**
- Specific organ function lab results (hematologic, hepatic, renal) are not provided.
- Confirmation if the patient has a tumor site appropriate for intratumoral injection is not explicit.

**Assessment:**
> The patient's cancer type, treatment history, age, and ECOG status align well with the trial's inclusion criteria. Although some organ function results and specific tumor site details are not provided, the evidence strongly suggests eligibility.

---

### [NCT04704661](https://clinicaltrials.gov/study/NCT04704661)

**Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has HER2-positive metastatic breast cancer, which matches the trial's inclusion of HER2-positive breast carcinoma.
- Patient has received at least one line of systemic chemotherapy for metastatic disease.
- Patient has progressed on anti-HER2 therapy, specifically trastuzumab and pertuzumab.
- ECOG status is 1.
- LVEF is 58%, which meets the trial's requirement of LVEF >= 50%.

**? Uncertainties:**
- Patient's specific laboratory values for platelet count, hemoglobin, absolute neutrophil count, creatinine clearance, AST/ALT levels, total bilirubin, leukocytes, albumin, INR/PTT are not provided.

**Assessment:**
> The patient has an eligible cancer type matching the trial's focus on HER2-positive breast carcinoma and has a history of previous therapies, meeting the criteria for previously treated patients. The ECOG status and LVEF are also acceptable, though there are some uncertainties regarding organ function lab values.

---

### [NCT05514717](https://clinicaltrials.gov/study/NCT05514717)

**A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2**

- **Sponsor**: Mersana Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has HER2-positive breast cancer, matching the study conditions.
- ECOG status is 1, which is acceptable for the trial.
- Patient has measurable disease as indicated by the mixed response and new liver lesions.
- No CNS disease, meeting the brain metastasis criteria.
- Patient has HER2 positivity defined as IHC 3+.

**? Uncertainties:**
- Fresh or archival tumor biopsy availability is uncertain based on the profile provided.
- No information on whether the patient is on immunosuppressive doses of systemic medications.

**Assessment:**
> The patient's cancer type matches the trial focus on HER2-positive tumors, and they have progressed after previous therapies, aligning with the inclusion criteria for recurrent metastatic disease. There are no significant exclusions or mismatches based on the provided information, hence a high likelihood of eligibility.

---

### [NCT06253871](https://clinicaltrials.gov/study/NCT06253871)

**A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations**

- **Sponsor**: Iambic Therapeutics, Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 48, which meets the age criterion of â‰¥ 18 years
- ECOG status is 1, which meets the ECOG criterion of 0-1
- Patient has HER2-positive metastatic breast cancer, aligning with the trial's studied conditions of HER2-positive Breast Cancer
- Patient's cancer is relapsed/refractory after prior treatments, fitting the trial's inclusion of relapsed/refractory HER2-altered malignancy
- LVEF is 58%, which meets the heart function criterion of â‰¥ 50%

**? Uncertainties:**
- Baselines for hematologic, liver, and renal function are not provided

**Assessment:**
> The patient's HER2-positive breast cancer matches the trial's target condition, and they have had prior systemic therapy, which aligns with the inclusion criteria for relapsed/refractory cases. No conflicts are identified, and although certain organ functions are not confirmed, they likely meet the requirements.

---

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT06695845](https://clinicaltrials.gov/study/NCT06695845)

**A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)**

- **Sponsor**: Jazz Pharmaceuticals
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has HER2 positive breast cancer, which is included in the trial conditions.
- Patient has an ECOG status of 1.

**âœ— Potential Conflicts:**
- Patient has had prior systemic therapies including TCHP, trastuzumab, pertuzumab, docetaxel, and T-DM1, which may not align with the requirement of 'previously treated patients' depending on cohort eligibility.

**? Uncertainties:**
- Patient's eligibility for Cohort 2 is unclear since it requires prior therapy with trastuzumab deruxtecan (T-DXd), which is not mentioned in the profile.

**Assessment:**
> The patient's breast cancer type matches the trial, and their ECOG status is acceptable. However, their extensive prior treatment history presents a conflict related to treatment line eligibility. Additionally, uncertainty exists regarding the specific requirement for trastuzumab deruxtecan in their treatment history.

---

## ðŸŸ  LOW Likelihood (2 trials)

### [NCT06055881](https://clinicaltrials.gov/study/NCT06055881)

**Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)**

- **Sponsor**: Mayo Clinic
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 30%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years
- ECOG status of 1
- No CNS disease

**âœ— Potential Conflicts:**
- Patient has metastatic breast cancer but does not have 12 months of clinical response to first-line therapy or 6 months of clinical response to second-line therapy.
- Patient has more than 3 extracranial sites of oligoprogressive disease (as indicated by new liver lesions).
- Patient has received multiple prior systemic therapies, which suggests that eligibility based on treatment line may not align.

**? Uncertainties:**
- Details on prior response duration to systemic therapies are not stated clearly in the profile.

**Assessment:**
> The patient's cancer type matches the trial, but they have not met the required treatment response timelines nor can it be clearly established given prior therapies. Additionally, the presence of new liver lesions raises further concerns about the oligoprogressive criteria.

---

### [NCT06551116](https://clinicaltrials.gov/study/NCT06551116)

**QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer**

- **Sponsor**: Abramson Cancer Center at Penn Medicine
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has HER2-positive metastatic breast cancer
- Patient's age is above 18
- ECOG status is 1

**âœ— Potential Conflicts:**
- Patient has a history of prior systemic therapies, including T-DM1, which conflicts with the trial's requirement for untreated (treatment-naive) patients.
- Patient has HER2 3+ by IHC, which is excluded as per the trial's exclusion criteria for Her2-overexpressing metastatic breast cancer.

**? Uncertainties:**
- No archival tissue availability is noted in the profile, which is a requirement for the trial.

**Assessment:**
> The patient has HER2-positive breast cancer but has previously received multiple lines of therapy, conflicting with the trial's requirement for treatment-naive patients. Additionally, the HER2 3+ status results in exclusion from the trial.

---

## Excluded (91 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02476786](https://clinicaltrials.gov/study/NCT02476786) | Patient age 48 is below minimum age 70 |
| [NCT04852887](https://clinicaltrials.gov/study/NCT04852887) | Patient age 48 is below minimum age 50 |
| [NCT00977977](https://clinicaltrials.gov/study/NCT00977977) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT01356290](https://clinicaltrials.gov/study/NCT01356290) | Patient age 48 is above maximum age 19 |
| [NCT02332668](https://clinicaltrials.gov/study/NCT02332668) | Patient age 48 is above maximum age 17 |
| [NCT04219254](https://clinicaltrials.gov/study/NCT04219254) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04253964](https://clinicaltrials.gov/study/NCT04253964) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04486352](https://clinicaltrials.gov/study/NCT04486352) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04585477](https://clinicaltrials.gov/study/NCT04585477) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04774718](https://clinicaltrials.gov/study/NCT04774718) | Patient age 48 is above maximum age 17 |
| [NCT05142592](https://clinicaltrials.gov/study/NCT05142592) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05239546](https://clinicaltrials.gov/study/NCT05239546) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05261399](https://clinicaltrials.gov/study/NCT05261399) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05281471](https://clinicaltrials.gov/study/NCT05281471) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05361720](https://clinicaltrials.gov/study/NCT05361720) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05797831](https://clinicaltrials.gov/study/NCT05797831) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05874193](https://clinicaltrials.gov/study/NCT05874193) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05916196](https://clinicaltrials.gov/study/NCT05916196) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05925803](https://clinicaltrials.gov/study/NCT05925803) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 26 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT04802759](https://clinicaltrials.gov/study/NCT04802759) | Hoffmann-La Roche | Patient is HER2 positive, but Cohort 1 is for HER2-negative breast cancer |
| [NCT04862663](https://clinicaltrials.gov/study/NCT04862663) | AstraZeneca | Trial focuses on HR+/HER2- breast cancer, while patient is HER2 positive. |
| [NCT05894239](https://clinicaltrials.gov/study/NCT05894239) | Hoffmann-La Roche | Patient has prior systemic therapy for locally advanced or metastatic HER2-positive breast cancer |
| [NCT06263543](https://clinicaltrials.gov/study/NCT06263543) | Reshma L. Mahtani, D | Patient has HER2 positive breast cancer, while the trial targets HER2 LOW/ULTRA LOW breast cancer. |
| [NCT06260033](https://clinicaltrials.gov/study/NCT06260033) | City of Hope Medical | Patient has received multiple lines of systemic therapy for metastatic disease (TCHP, trastuzumab, pertuzumab, docetaxel, T-DM1). The trial excludes patients who have received more than three lines of systemic therapy. |
| [NCT06671912](https://clinicaltrials.gov/study/NCT06671912) | Alliance for Clinica | Patient has HER2-positive breast cancer, but the trial requires HER2-negative breast cancer. |
| [NCT04074720](https://clinicaltrials.gov/study/NCT04074720) | Thomas Jefferson Uni | The trial aims to study patients undergoing definitive surgical tumor resection or placement of a vascular access device, and the patient is currently undergoing systemic therapy (T-DM1 ongoing) without indication of a prior surgical intervention. |
| [NCT02945579](https://clinicaltrials.gov/study/NCT02945579) | M.D. Anderson Cancer | Patient has previously treated breast cancer with multiple lines of therapy, while the trial may focus on treatment-naive patients as it mentions neoadjuvant systemic therapy. |
| [NCT05396612](https://clinicaltrials.gov/study/NCT05396612) | Abramson Cancer Cent | Patient has metastatic breast cancer which does not match trial's inclusion criteria for non-metastatic breast cancer. |
| [NCT05488145](https://clinicaltrials.gov/study/NCT05488145) | Emory University | Patient has HER2-positive breast cancer, but the trial excludes HER2-positive patients. |
| [NCT05659797](https://clinicaltrials.gov/study/NCT05659797) | Abramson Cancer Cent | Patient has received prior systemic therapy (TCHP, trastuzumab, pertuzumab, docetaxel, T-DM1), while the trial appears to target treatment-naive patients. |
| [NCT05996107](https://clinicaltrials.gov/study/NCT05996107) | University of Michig | Patient has HER2-positive breast cancer, while the trial is for ER+/HER2-negative breast cancer. |
| [NCT06401889](https://clinicaltrials.gov/study/NCT06401889) | Mayo Clinic | Patient has received prior chemotherapy (trastuzumab/pertuzumab + docetaxel) and is currently receiving T-DM1, while the trial excludes patients who have previously taken AIs or who have received any prior chemotherapy or endocrine therapy for their current breast cancer. |
| [NCT05256225](https://clinicaltrials.gov/study/NCT05256225) | National Cancer Inst | Patient has breast cancer, but the trial is focused on endometrial cancer. |
| [NCT04958239](https://clinicaltrials.gov/study/NCT04958239) | Boehringer Ingelheim | Patient has breast cancer (HER2 positive) while the trial is focused on head and neck squamous cell carcinoma (HNSCC). |
| [NCT06084481](https://clinicaltrials.gov/study/NCT06084481) | AbbVie | Patient has HER2 positive breast cancer; trial excludes HER2 positive breast cancer as it specifically studies HR+/HER2- breast cancer. |
| [NCT06099769](https://clinicaltrials.gov/study/NCT06099769) | Memorial Sloan Kette | Patient has HER2-positive breast cancer, while trial is for AR+ metastatic triple-negative or ER-low breast cancer. |
| [NCT06361940](https://clinicaltrials.gov/study/NCT06361940) | Medical College of W | Patient has HER2 positive breast cancer, trial is for HER2 negative breast cancer |
| [NCT06374459](https://clinicaltrials.gov/study/NCT06374459) | Washington Universit | Patient has HER2 positive breast cancer, while the trial is specifically for HER2 negative metastatic breast cancer. |
| [NCT06525766](https://clinicaltrials.gov/study/NCT06525766) | Mayo Clinic | Patient has HER2 positive breast cancer while the trial requires HER2 negative breast cancer. |
| ... | ... | *and 25 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| ER positive | manual | 1.0 |
| ERpositive | manual | 0.9 |
| ER-positive | manual | 0.9 |
| PR negative | manual | 1.0 |
| PRnegative | manual | 0.9 |
| PR-negative | manual | 0.9 |
| breast cancer | manual | 1.0 |
| HER2 positive breast cancer | manual | 1.0 |
| ER positive breast cancer | manual | 1.0 |
| PR negative breast cancer | manual | 1.0 |
| metastatic breast cancer | llm | 0.8 |
| MBC | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **PD-L1 expression status** - required by several trials for cohort assignment
- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
